Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bioassay and Potency Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bioassay and Potency Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical quality control managers ensuring batch-to-batch consistency, regulatory affairs specialists preparing biologic license applications, and CROs supporting drug development programs, understanding the evolving Bioassay and Potency Testing market is critical to compliance and product safety. The global market for Bioassay and Potency Testing was estimated to be worth US716millionin2025andisprojectedtoreachUS716millionin2025andisprojectedtoreachUS 997 million, growing at a CAGR of 4.9% from 2026 to 2032. Bioassays and potency testing refer to experimental procedures that assess the activity, function, or efficacy of substances (such as drugs, vaccines, and biologics) through biological methods. Bioassay testing utilizes living tissues, cells, microorganisms, or biomolecular systems to quantitatively measure the response of a test sample to a specific biological effect, such as pharmacological activity, toxicity, immune response, or enzymatic activity, thereby determining potency, dose-response relationships, and batch-to-batch consistency. These tests are widely used in drug development analytics, biologics quality control, and regulatory submissions, and are critical for ensuring the safety, efficacy, and quality of biologic products. Unlike chemical potency methods (HPLC, mass spectrometry) which measure structural attributes, bioassays measure functional activity – essential for complex biologics where structure does not perfectly predict function (e.g., antibodies, cell therapies, gene therapies).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095551/bioassay-and-potency-testing
1. Competitive Landscape and Key Players
The competitive landscape of the Bioassay and Potency Testing market is characterized by a mix of global contract research organizations (CROs), specialized bioanalytical labs, and niche assay development firms. Key players include Eurofins (Luxembourg), Vimta Labs Ltd. (India), WaveCyte BioLabs (US), Reaction Biology (US), Charles River Laboratories (US), Intertek (UK), Pacific BioLabs (US), FyoniBio (Germany), Svar Life Science (Sweden), Solvias (Switzerland), Bioassay GmbH (Germany), and Clean Cells (France).
Charles River Laboratories and Eurofins lead the global market, leveraging extensive laboratory networks, broad regulatory expertise (FDA, EMA, NMPA), and end-to-end drug development services (from discovery to commercialization). Charles River has particular strength in potency assays for cell and gene therapies, while Eurofins leads in vaccine bioassays and batch release testing. FyoniBio and Clean Cells are European specialists in cell-based potency assays for biosimilars and monoclonal antibodies. Recent strategic developments observed in the past six months (Q4 2025–Q1 2026) include Charles River Laboratories’ acquisition of a cell-based assay platform from a biotech startup, enhancing its high-throughput potency screening capabilities for gene therapy vectors. Eurofins expanded its bioassay capacity in Singapore to serve Asia-Pacific vaccine manufacturers. WaveCyte BioLabs launched a ready-to-use potency assay kit for adeno-associated virus (AAV) gene therapies, reducing method development time from 6 months to 2 weeks. Vimta Labs received WHO prequalification for its vaccine potency testing services, enabling participation in global health tenders.
Industry Insight – Biologics Quality Control Outsourcing vs. In-House Dynamics: The potency testing market is divided between in-house testing at biopharmaceutical manufacturers (particularly large pharma with dedicated QC labs) and outsourced testing to CROs (small-to-mid-sized biotechs, virtual manufacturers, and companies lacking specialized cell-based assay expertise). The outsourcing segment has grown at 6-7% annually, driven by increasing complexity of biologics (cell therapies requiring specialized cell lines and handling), regulatory pressure for independent lot release testing (some markets require third-party testing for certain products), and the capital-intensive nature of cell-based assay development (requiring specialized equipment, cell culture facilities, and trained scientists). However, large pharma companies (e.g., Roche, Pfizer, Novartis) maintain extensive in-house potency testing capabilities for their core products, only outsourcing for overflow or specialized assays.
2. Market Segmentation by Type and Application
2.1 By Type: In Vitro Assay vs. In Vivo Assay
The Bioassay and Potency Testing market is segmented by methodology into In Vitro Assay (cell-based, biochemical, or molecular assays performed in controlled laboratory conditions) and In Vivo Assay (animal-based assays where test samples are administered to live animals). In Vitro Assays currently dominate with approximately 78% of global market share in 2025, driven by the industry-wide push to replace animal testing (3Rs principles: Replacement, Reduction, Refinement), faster turnaround (hours to days vs. weeks for in vivo), higher throughput (96- or 384-well plates enabling multiple samples), and lower cost (typically 50-70% less than in vivo). In vitro assays are preferred for most biologics including monoclonal antibodies, recombinant proteins, and gene therapies. In Vivo Assays account for 22% of the market, still required for certain products where in vitro alternatives lack regulatory acceptance (e.g., some vaccine potency tests, certain toxins, and products with complex mechanisms requiring intact physiological systems). The in vivo segment is declining at -1% CAGR as regulatory agencies accept more cell-based alternatives.
2.2 By Application: Drug Development, Scientific Research, and Other
In terms of application, the Bioassay and Potency Testing market is broadly classified into Drug Development (including discovery, preclinical, clinical, and post-approval QC), Scientific Research (academic and nonprofit research using bioassays for basic biology), and Other (environmental testing, food safety, forensic applications). Drug Development currently dominates with approximately 70% of global consumption, driven by the expanding biologics pipeline (over 7,000 biologics in development globally as of 2025), regulatory requirements for potency testing for all biologic license applications, and post-approval stability testing (potency as a critical quality attribute). Scientific Research accounts for approximately 25% of consumption, including academic studies of cell signaling, toxicology, and pharmacology using bioassay methods. The Other segment (5%) includes environmental toxicity testing and food allergen detection.
Industry Insight – Drug Development vs. QC Application Differences: The cell-based assay market for drug development (discovery and preclinical) differs significantly from QC potency testing. Discovery bioassays prioritize throughput and flexibility, often using generic cell lines and standard reagents, with acceptable inter-assay variability of 15-20%. These assays help rank compound potency, select lead candidates, and understand mechanism of action. In contrast, QC potency assays for approved biologics require rigorous validation (per ICH Q2), low inter-assay variability (typically <10%), and long-term stability to support product shelf-life claims. QC assays must be transferable across manufacturing sites and withstand regulatory inspection. This divergence creates different customer requirements: discovery teams seek speed and menu breadth; QC teams seek robustness, compliance documentation, and technology transfer support. CROs offering both services must maintain distinct operational and quality systems.
3. Market Drivers, Restraints, and Technical Challenges
3.1 Key Drivers
- Biologics market growth: Global biologics sales exceeded US$ 450 billion in 2025, with potency testing representing 0.15-0.20% of biologics revenue
- Regulatory requirements: ICH Q6B requires potency assays for all biologics; FDA, EMA, and other agencies demand lot release and stability testing
- Biosimilar development: Over 100 biosimilars in development globally, each requiring extensive potency comparability studies (vs. reference product)
- Complex modalities: Cell therapies (CAR-T), gene therapies (AAV), mRNA vaccines require novel, product-specific bioassay development (not off-the-shelf)
- 3Rs pressure: Regulatory and societal push to replace animal-based potency tests; driving innovation in cell-based alternatives
3.2 Technical Challenges and Industry Gaps
Despite stable market forecast growth, the Bioassay and Potency Testing market faces significant technical challenges. Assay variability remains the primary headache – cell-based assays typically exhibit 15-20% inter-assay variability (vs. 2-5% for HPLC), making it difficult to establish tight specification limits and causing batch release delays. A QYResearch industry survey (December 2025) found that 52% of QC laboratories reported potency assay out-of-specification (OOS) results attributable to assay variability rather than product quality issues, leading to costly investigations. Cell line stability – bioassays using continuously passaged cell lines drift over time, requiring frequent qualification and potentially invalidating long-term stability studies. Method transfer challenges – transferring a potency assay from a sponsor to a CRO, or from development to QC, typically takes 6-12 months and extensive bridging studies. New modality challenges – for gene therapies (AAV vectors), measuring “potency” is complex: should it measure vector genome copy number, transgene expression in target cells, or functional protein production? Regulatory guidance is still evolving. Turnaround time – typical cell-based potency assays take 3-7 days, creating bottlenecks in lot release (biologics may be quarantined awaiting results).
Technical Parameter Insight: For CRO selection and assay development, key evaluation criteria include:
- Assay format: 96-well plate (standard throughput) vs. 384-well (high-throughput) vs. high-content imaging (for morphological endpoints)
- Cell line: Primary cells (more physiologically relevant but variable) vs. immortalized cell lines (more consistent but less relevant)
- Readout: Luminescence (ATP, reporter gene), fluorescence (calcium flux, FRET), absorbance (ELISA, colorimetric), or imaging
- Validation parameters: Accuracy (spike recovery), precision (repeatability, intermediate precision), specificity (interference from excipients, degraded product), linearity, range, robustness
- Regulatory documentation: Does the CRO provide ICH Q2-compliant validation reports suitable for regulatory submission?
- Technology transfer: Does the CRO use “ready-to-use” assay kits that simplify transfer, or complex custom assays requiring intensive training?
4. Regional Market Dynamics and Forecast 2026-2032
North America currently leads the Bioassay and Potency Testing market with a market share of 45% in 2025, driven by the world’s largest biologics industry (US accounts for over 40% of global biologics sales), extensive CRO infrastructure, and early adoption of advanced cell-based assays. The US market alone accounts for over US$ 300 million in annual bioassay and potency testing services.
Europe accounts for approximately 30% market share, led by Germany (large biopharma presence), Switzerland (CRO hub), and the UK (cell and gene therapy cluster). Europe has been at the forefront of 3Rs implementation, with several countries (Netherlands, Germany, UK) actively funding development of animal-free potency test alternatives.
Asia-Pacific holds approximately 20% market share and is the fastest-growing region (CAGR 7.5% through 2032), driven by China’s rapidly expanding biologics industry (over 500 biologics in development as of 2025), India’s vaccine manufacturing capacity (largest vaccine producer globally), and Japan/South Korea’s biopharma sectors. China’s NMPA has harmonized potency testing requirements with ICH, driving demand for qualified CROs. Indian CROs like Vimta Labs offer cost advantages (30-50% lower than Western CROs) for bioassay development and validation.
Rest of World (Latin America, Middle East, Africa) accounts for approximately 5% of sales, with limited bioassay capacity beyond basic microbiology.
Industry Insight – Potency Testing for Vaccines vs. Therapeutic Biologics: The biologics quality control market shows distinct product-specific dynamics. Vaccine potency testing historically relied on in vivo assays (e.g., animal challenge models), but regulatory agencies are increasingly accepting cell-based alternatives. For example, the FDA has approved cell-based potency assays for several viral vaccines (HPV, hepatitis B, influenza). However, for certain vaccines (e.g., pertussis, diphtheria, tetanus toxoids), the compendial in vivo assays remain required in many pharmacopoeias (USP, EP, JP), creating an ongoing market for in vivo potency testing. Therapeutic biologics (mAbs, recombinant proteins, cell therapies) predominantly use cell-based in vitro potency assays, with increasing adoption of mechanism-of-action assays (measuring functional activity) rather than binding assays (measuring target binding only). Gene therapies present the newest challenge: regulatory guidance recommends “multi-tiered” potency testing, measuring both vector attributes and functional activity in target cells.
5. Future Outlook and Strategic Recommendations
Based on the market forecast, the global Bioassay and Potency Testing market is expected to reach US$ 997 million by 2032, representing a CAGR of 4.9%. Key growth opportunities lie in developing high-throughput cell-based potency assays for gene therapy and cell therapy products (reducing turnaround time from weeks to days), ready-to-use potency assay kits for common biologics (monoclonal antibodies, Fc-fusion proteins) to reduce method development burden, AI and machine learning for assay data analysis (automated curve fitting, outlier detection, assay drift prediction), and regulatory-accepted in vitro alternatives for vaccines still requiring animal testing. Vendors should prioritize assay automation and high-throughput capabilities to reduce turnaround time and variability, develop industry-specific potency assay panels (oncology mAbs, inflammation mAbs, gene therapies), invest in cell line engineering to improve assay consistency (reporter cell lines, stable expression systems), and build regulatory affairs expertise to guide clients through potency assay validation and submission. For biopharmaceutical companies, it is recommended to develop potency assays early in product development (not left for late-stage), qualify multiple cell banks to mitigate cell line stability risk, implement robust assay control strategies (reference standards, system suitability criteria, trending), and consider outsource partners with demonstrated regulatory track records for similar product types.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
